WHO says no to extending Covishield shelf-life to 9 months
PTI
New Delhi |
Updated on
April 08, 2021
× Citing insufficient data, WHO has rejected Serum Institute of India’s proposal seeking extension of the shelf life of the Oxford-AstraZeneca Covid-19 vaccine, Covishield, from six to nine months, sources said.
The WHO has also sought a meeting with the Drugs Controller General of India (DCGI) to discuss the matter, they said. The move comes even as the DCGI has extended Covishield’s shelf-life from six to nine months from its manufacturing date. In a recent communique to Pune-based Serum Institute, the WHO also asked the firm to formulate doses of a higher specification so that the minimum specification of ≥2.5x108 ifu/dose is fulfilled throughout the shelf-life.
WHO rejects Serum Institute s proposal seeking extension of Covishield s shelf life
The move comes even as India s drug regulator has extended Covishield s shelf life from six to nine months from its manufacturing date.
Share Via Email
| A+A A- By PTI
NEW DELHI: The WHO has rejected Serum Institute of India s proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said.
The WHO has also sought a meeting with Drugs Controller General of India (DCGI) to discuss the matter, they said.
The move comes even as India s drug regulator has extended Covishield s shelf life from six to nine months from its manufacturing date.
The WHO has rejected Serum Institute of India s proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said. The WHO has also sought a meeting with Drugs Controller General of India (DCGI) to discuss the matter, they said. The move comes even as India s drug regulator has extended Covishield s shelf life from six to nine months from its manufacturing date. In a recent communique to Pune-based Serum Institute of India (SII), the WHO has also asked the firm to formulate the doses with enough titer and/or implement a higher specification at release so that the minimum specification of= 2.5 x108ifu/dose is fulfilled throughout the shelf life.
India Vaccine Shortfall Hits Key Financial Hub As COVID-19 Surges Again ibtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com Daily Mail and Mail on Sunday newspapers.
WHO rejects SII s proposal seeking extension of Covishield s shelf life from 6 to 9 months
Published: Share Tweet
Recipient s Name
Send The move comes even as India s drug regulator has extended Covishield s shelf life from six to nine months from its manufacturing date.
Representative Image
New Delhi:
The WHO has rejected Serum Institute of India s proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said.
The WHO has also sought a meeting with Drugs Controller General of India (DCGI) to discuss the matter, they said.
The move comes even as India s drug regulator has extended Covishield s shelf life from six to nine months from its manufacturing date.